Insulin and insulin-like growth factors (IGFs) have been implicated in the pathogenesis of diabetic retinopathy and peripheral vascular complications. Previously, we have shown that retinal capillary endothelial cells responded to insulin and IGFs for metabolic and growth effects, whereas aortic endothelial cells were not responsive. In contrast, vascular supporting cells from both retinal capillaries (i.e. pericytes) and aorta (i.e. smooth muscle cells) responded equally to insulin, IGF-I, and IGF-II.

The structure and ligand specificities of the receptor for these peptides were studied by covalently cross-linking ¹²⁵I-labeled peptide hormones to their respective receptors using disuccinimidyl suberate, followed by polyacfylamide gel electrophoresis and autoradiography. The binding subunit of the insulin receptor, α-subunit, for all cell types was found to have a mol wt 145,000 under reduced conditions. Labeling of this band was inhibited by 10⁻⁹m insulin, antiinsulin receptor antibodies, and 10⁻⁸m IGF-I, but not by multiplication-stimulating activity (IGF-II). The β-subunit of the insulin receptor in endothelial cells wasidentified by its ability to be autophosphorylated when stimulated by insulin and was found to have a mol wt of 99,000.

Covalent cross-linking of IGF-I to its receptor revealed a mol wt of 145,000, similar to that of insulin receptor, except that IGF-I was 100-fold more potent than insulin in competing with [¹²⁵I]IGF-I for binding. [¹²⁵I]IGF-II in all cells was cross-linked to receptor with mol wt of 260,000 and 230,000 under reduced and nonreduced conditions, respectively. IGF-I competed weakly with [¹²⁵I]IGF-II, whereas insulin was ineffective. [¹²⁵I]IGF-II also bound to the band with a mol wt of 135,000, which was inhibited by insulin, IGF-I, and IGF-II.

In summary, receptors for insulin, IGF-I, and IGF-II on cells from micro- and macrovessels are biochemically similar to those in other cells. Interestingly, the finding of large numbers of IGFI and IGF-II receptors on endothelial cells suggests that these growth factors play a physiological role and are involved in vascular complications associated with diabetes. {Endocrinology117:1222–1229,1985)